PriceTargets.com logo

Reunion Neuroscience - REUN Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $15.50
  • Forecasted Upside: 1,283.93%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.12 As of 08/1/2023 01:00 AM ET
+0 (0.00%)
Get New Reunion Neuroscience Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for REUN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for REUN

Analyst Price Target is $15.50
▲ +1,283.93% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Reunion Neuroscience in the last 3 months. The average price target is $15.50, with a high forecast of $20.00 and a low forecast of $11.00. The average price target represents a 1,283.93% upside from the last price of $1.12.

This chart shows the closing price for REUN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 5 polled investment analysts is to moderate buy stock in Reunion Neuroscience. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/3/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/2/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/2/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/31/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/29/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/27/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/1/2023Bloom BurtonDowngradeBuy ➝ HoldLow
5/1/2023ThinkEquityInitiated CoverageBuyLow
3/15/2023Stifel NicolausDowngradeBuy ➝ HoldLow
2/15/2023HC WainwrightReiterated RatingBuy$20.00Low
2/14/2023EF Hutton Acquisition Co. IReiterated RatingBuy$11.00Low
12/16/2022EF Hutton Acquisition Co. IInitiated CoverageBuy$11.00Low
11/28/2022Bloom BurtonReiterated RatingBuyLow
11/15/2022Stifel NicolausLower TargetC$15.00 ➝ C$5.50Low
(Data available from 11/28/2018 forward)

News Sentiment Rating

0.09 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/2/2023
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/1/2023
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/1/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/31/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/30/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Reunion Neuroscience logo
Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company's lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications. The company was formerly known as Field Trip Health Ltd. Reunion Neuroscience Inc. was founded in 2008 and is headquartered in Toronto, Canada.
Read More

Today's Range

Now: $1.12
Low: $1.12
High: $1.12

50 Day Range

MA: $1.12
Low: $1.11
High: $1.13

52 Week Range

Now: $1.12
Low: $0.63
High: $5.07

Volume

N/A

Average Volume

210,209 shs

Market Capitalization

$13.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.29

Frequently Asked Questions

What sell-side analysts currently cover shares of Reunion Neuroscience?

The following equities research analysts have issued research reports on Reunion Neuroscience in the last twelve months: Bloom Burton, EF Hutton Acquisition Co. I, HC Wainwright, Stifel Nicolaus, and ThinkEquity.
View the latest analyst ratings for REUN.

What is the current price target for Reunion Neuroscience?

2 Wall Street analysts have set twelve-month price targets for Reunion Neuroscience in the last year. Their average twelve-month price target is $15.50, suggesting a possible upside of 1,283.9%. HC Wainwright has the highest price target set, predicting REUN will reach $20.00 in the next twelve months. EF Hutton Acquisition Co. I has the lowest price target set, forecasting a price of $11.00 for Reunion Neuroscience in the next year.
View the latest price targets for REUN.

What is the current consensus analyst rating for Reunion Neuroscience?

Reunion Neuroscience currently has 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for REUN.

What other companies compete with Reunion Neuroscience?

Other companies that are similar to Reunion Neuroscience include UpHealth, Pear Therapeutics, EUDA Health, GeneDx and Virios Therapeutics. Learn More about companies similar to Reunion Neuroscience.

How do I contact Reunion Neuroscience's investor relations team?

Reunion Neuroscience's physical mailing address is 30 DUNCAN STREET SUITE 400, TORONTO A6, M5V 2C3. The company's listed phone number is 1-833-222-0084 and its investor relations email address is [email protected]. The official website for Reunion Neuroscience is www.reunionneuro.com. Learn More about contacing Reunion Neuroscience investor relations.